Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31710474 | 0.98 | ALOX5 (0.42) | ALOX5KCNH2SCN5ABCHEACHE | |
| SCHEMBL3524929 | 0.86 | KCNH2 (0.42) | KCNH2SCN5A | |
| SCHEMBL14372289 | 0.80 | KCNH2 (0.36) | KCNH2SCN5A | |
| SCHEMBL3518926 | 0.78 | KCNH2 (0.40) | KCNH2SCN5A | |
| SCHEMBL9377662 | 0.77 | KCNH2 (0.40) | KCNH2SCN5A | |
| SCHEMBL9381481 | 0.77 | KCNH2 (0.40) | KCNH2SCN5A | |
| SCHEMBL9377290 | 0.76 | KCNH2 (0.39) | KCNH2SCN5A | |
| SCHEMBL9381651 | 0.76 | KCNH2 (0.39) | KCNH2SCN5A | |
| SCHEMBL14372255 | 0.76 | POLB (0.38) | — | |
| SCHEMBL31642676 | 0.74 | KCNH2 (0.38) | KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | claimed |
| WO-2023225041-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | claimed |
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023225041-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025912-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | ALOX5 2770/4885KCNH2 4407/4885SCN5A 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.